Identification and management of patients at high bleeding risk undergoing percutaneous
coronary intervention are of major importance, but a lack of standardization in defining this …

This white paper provides a summary of a scientific proposal presented at a Cardiac Safety
Research Consortium/Health and Environmental Sciences Institute/Food and Drug …

This publication describes uniform definitions for cardiovascular and stroke outcomes
developed by the Standardized Data Collection for Cardiovascular Trials Initiative and the US …

The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is
projected to worsen. To date, there are no approved therapies available for reducing mortality …

The early and efficient assessment of cardiac safety liabilities is essential to confidently advance
novel drug candidates. This article discusses evolving mechanistically based preclinical …

The implementation of the ICH S7B and E14 guidelines has been successful in preventing
the introduction of potentially torsadogenic drugs to the market, but it has also unduly …

Drug-induced torsade de pointes (TdP) is a potentially fatal iatrogenic entity. Its reporting
rate in association with non-cardiac drugs increased exponentially from the early 1990s and …

To assess the utility of human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs)
as an in vitro proarrhythmia model, we evaluated the concentration dependence and …

The criterion for assessing whether a drug prolongs QT as described in the International
Conference on Harmonization topic E14 guideline does not explicitly account for individual drug …

Endpoint selection is a critically important step in clinical trial design. It poses major challenges
for investigators, regulators, and study sponsors, and it also has important clinical and …